ARA-290

ARA-290 (Cibinetide)

Primary Function: Inflammation modulation, neuropathic pain reduction, tissue protection
Research Use: Neuropathy, autoimmune inflammation, erythropoietin receptor research
Molecular Formula: C105H165N33O27
CAS Number: 75517-55-8
Synonyms: Cibinetide, EPO-mimetic peptide, Innate Repair Receptor (IRR) agonist

Description:
ARA-290 is a synthetic 8-amino acid peptide derived from the structure of erythropoietin (EPO) but designed to exclude erythropoiesis while preserving EPO’s tissue-protective and anti-inflammatory benefits. It activates the Innate Repair Receptor (IRR)—a heteromeric receptor composed of EPOR and CD131—leading to immune modulation, neuropathic pain relief, and vascular repair without stimulating red blood cell production. ARA-290 is actively studied for its potential in treating small fiber neuropathy, inflammatory conditions, and autoimmune disorders.

Mechanism of Action:

• Selectively activates the Innate Repair Receptor (IRR)
• Suppresses pro-inflammatory cytokine release (e.g., TNF-α, IL-6)
• Promotes neurovascular regeneration and endothelial repair
• Does not stimulate erythropoiesis or impact hematocrit levels

Key Research Areas:

• Small fiber neuropathy (e.g., sarcoidosis, diabetes-related)
• Chronic inflammation and autoimmune modulation
• Vascular protection and endothelial repair
• Neuropathic pain and neuroinflammation

History of Discovery:
ARA-290 was developed by Araim Pharmaceuticals in collaboration with Dr. Maarten van Greevenbroek’s team, as part of a targeted program to harness EPO’s cytoprotective properties without increasing red blood cell mass. The peptide emerged as a highly specific IRR agonist, with promising results in both preclinical and early-phase clinical trials, particularly in neuropathic pain syndromes.

Case Studies:

1. Sarcoidosis-Associated Neuropathy (2013, Sarcoidosis Vasc Diffuse Lung Dis): ARA-290 significantly improved small fiber nerve function and reduced pain in sarcoidosis patients after just 28 days. [Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(3):208–215.]
2. Diabetic Neuropathy (2014, Mol Pain): Mice with diabetes-induced small fiber neuropathy treated with ARA-290 showed reduced inflammation and restored nerve fiber density. [Mol Pain. 2014;10:45.]
3. Endothelial Protection in Inflammation (2012, PLoS One): ARA-290 preserved vascular integrity and reduced capillary leak in inflammatory models. [PLoS One. 2012;7(7):e41141.]

Packaging Information:

• Form: Lyophilized powder
• Purity: ≥ 99%
• Storage: Store at -20°C in a dry, dark environment
• For research use only. Not for human or veterinary use.